GSGustavo Figueiredo da Silva

Gustavo Figueiredo da Silva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gustavo Figueiredo da Silva has a total of 36 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Incidence of cardioembolic stroke related to atrial fibrillation in Joinville, Brazil

    by Henrique Diegolli, Raddib Eduardo Noleto da Nobrega Oliveira, Caroline Figueiredo da Silva, Gustavo Figueiredo da Silva, Felipe Fanine de Souza, Felipe Reinert Avilla Machado, Marcelo Pitombeira de Lacerda

    Background Atrial fibrillation (AF) is an important cause of cardioembolic stroke, and population aging has increased its prevalence. Objective To evaluate the incidence of cardioembolic stroke caused by AF in the city of Joinville, Brazil, as well as previous diagnoses and use of medication. Methods Between 2017 and 2020 we extracted data from the population-based Joinville Stroke Registry. Demographic characteristics, diagnosis of AF, and patterns of medication use were collected, and the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) system was used to classify the etiology. Results There were 3,303 cases of ischemic stroke, 593 of which were cardioembolic, and 360 had AF. Of the patients with AF, 258 (71.6%) had a previous diagnosis of the disease, and 102 (28.3%) were newly diagnosed after the stroke. Among patients with a previously-diagnosed AF, 170 (47.2%) were using anticoagulants, and 88 (24.4%) were using other medications. Conclusion During the analyzed period, ischemic stroke caused by AF was a significant burden on the population of Joinville, and a considerable number of patients had undiagnosed or untreated AF.


  • Open Access

    Impact of pharmacogenetics on aspirin resistance: a systematic review

    by Gustavo Figueiredo da Silva, Bruno Mattei Lopes, Vinicius Moser, Leslie Ecker Ferreira

    Background Pharmacogenetics promises better control of diseases such as cardiovascular disease (CVD). Acetylsalicylic acid, aspirin, prevents the formation of an activating agent of platelet aggregation and vasoconstriction, and it is used to prevent CVD. Nevertheless, patients may have treatment failure due to genetic variants that modify the metabolism of the drug causing aspirin resistance (AR).Objectives To realize a systematic literature review to determine the impact of genetic variants on AR.Methods Articles published in the MEDLINE/PubMed, Cochrane, Scopus, LILACS, and SCIELO databases were systematically screened. A total of 290 articles were identified and 269 articles were excluded because they did not comply with the previously established inclusion criteria. A total of 20 case-control studies and 1 cohort was included.Results The genetic variants rs1126643 (ITGA2), rs3842787 (PTGS1), rs20417 (PTGS2), and rs5918 (ITGB3) were the most studied. As for relevance, of the 64 genetic variants evaluated by the articles, 14 had statistical significance (p < 0.05; 95% confidence interval [CI]) in at least one article. Among them, the following have had unanimous results: rs1371097 (P2RY1), rs1045642 (MDR1), rs1051931 and rs7756935 (PLA2G7), rs2071746 (HO1), rs1131882 and rs4523 (TBXA2R), rs434473 (ALOX12), rs9315042 (ALOX5AP), and rs662 (PON1), while these differ in real interference in AR: rs5918 (ITGB3), rs2243093 (GP1BA), rs1330344 (PTGS1), and rs20417 (PTGS2). As study limitations, we highlight the nonuniform methodologies of the analyzed articles and population differences.Conclusion It is noteworthy that pharmacogenetics is an expanding area. Therefore, further studies are needed to better understand the association between genetic variants and AR.


  • Open Access

    Response to “Nerve conduction studies support the classification of SARSCoV‐2 associated Guillain‐Barre subtypes”

    by Gustavo Figueiredo Silva, Caroline Figueiredo Silva, Raddib Eduardo Noleto Nobrega Oliveira, Fabiana Romancini, Rafael Marques Mendes, Amanda Locks, Maria Francisca Moro Longo, Carla Heloisa Cabral Moro, Alexandre Luiz Longo, Vera Lucia Braatz

  • Open Access

    Transverse myelitis and coronavirus disease 2019 vaccine: A temporal association

    by Gustavo Figueiredo da Silva, Caroline Figueiredo da Silva, Raddib Eduardo Noleto da Nobrega Oliveira, Felipe William Dias Silva, João Pedro Ribeiro Baptista, Sabrina Hafemann Loz, Carla Heloisa Cabral Moro, Alexandre Luiz Longo², Gustavo da Cunha Ribas

    Background: Transverse myelitis (TM) is most often triggered by an autoimmune reaction due to infections and perhaps vaccines. During the current coronavirus disease 2019 (COVID‐19) pandemic, some case reports have shown a temporal association between TM and COVID‐19 vaccine. We aimed to report a case of TM with a temporal association with ChAdOx1 nCoV‐19 (AZD1222, Oxford/AstraZeneca) vaccine in a Brazilian public hospital.Case Presentation: A 27‐year‐old woman experienced fever, low back pain and urinary retention 3 weeks after the first dose of the ChAdOx1 nCoV‐19 vaccine. Two days later, she experienced decreased strength of the lower limbs associated with paresthesia of the distal extremities. At the hospital, there was progression of weakness associated with anesthesia in T4‐L1. Magnetic resonance imaging findings were suggestive of demyelination and acute inflammation. Cerebrospinal fluid analysis showed monomorphonuclear pleocytosis, increased protein and decreased glucose. Gram stain, oligoclonal bands, anti‐aquaporin‐4 antibody, and screening for infectious agents and connective tissue disease were all negative. During treatment, the patient received 5‐day pulse therapy with methylprednisolone, acyclovir and 7‐day plasmapheresis. Despite all treatments, she persisted with lower limb plegia, areflexia and anesthesia at the level of T4. She was discharged with a monthly cyclophosphamide plan and outpatient follow up.Conclusions: In the absence of other causes, the diagnosis of TM was made with evidence of a possible temporal association with ChAdOx1 nCoV‐19 vaccine. It is important to emphasize that it is a temporal association only and the benefits of vaccination continue to outweigh the risk of TM.


  • Open Access

    Guillain–Barré syndrome after coronavirus disease 2019 vaccine: A temporal association

    by Gustavo Figueiredo da Silva, Caroline Figueiredo da Silva, Raddib Eduardo Noleto da Nobrega Oliveira, Fabiana Romancini, Rafael Marques Mendes, Amanda Locks, Maria Francisca Moro Longo, Carla Heloisa Cabral Moro, Alexandre Luiz Longo, Vera Lucia Braatz

    Background: Guillain–Barré syndrome (GBS) is an acute monophasic immune‐mediated polyradiculoneuropathy, preceded by gastrointestinal or respiratory infections in up to two‐thirds of patients. On rare occasions, people develop GBS after vaccination, but no causal association has been proven. In the current coronavirus disease 2019 (COVID‐19) pandemic, some cases have been reported associating COVID‐19 vaccine with GBS.Case presentation: We report a case of a 62‐year‐old woman with GBS after the first dose of the Oxford/AstraZeneca vaccine against SARS‐CoV‐2. The symptoms started 3 weeks after the vaccine, and were characterized by ascending and progressive paresthesia in the upper and lower limbs, followed by loss of strength of the upper limbs and dysphagia for solids. The hypothesis of GBS was confirmed by clinical presentation compatible with albuminocytologic dissociation in cerebrospinal fluid and based on the Brighton criteria level 2. The treatment was a 5‐day course of intravenous immunoglobulin with an improvement of symptoms.Conclusions: In the absence of other causes, the diagnosis of GBS was made, with evidence of a clear temporal association with COVID‐19 vaccine. However, a cautious position is important when assigning a particular side‐effect directly to a vaccine. It is important to emphasize that it is a temporal association only and the benefits of COVID‐19 vaccination continue to outweigh the possible consequences.


  • Open Access

    Small-fiber neuropathy and celiac disease: A narrative review

    by Gustavo Figueiredo da Silva, Giulia Murillo Wollmann, Luana Schlindwein Imhof, Marina Steingräber Pereira, Matheus Fellipe Nascimento de Souza, André Eduardo de Almeida Franzoi, Marcus Vinicius Magno Gonçalves

    Background: Neurological manifestations of celiac disease (CD) have a prevalence of 10% to 22% among patients. Of this group, neuropathy is present in up to 23%, with small fiber neuropathy (SFN) being the most described, with a predominance of painful symptoms and appendicular paresthesia. Objectives: Review literature to describe the clinical management of SFN in CD. Design and setting: Narrative review. Methods: Non-systematic review on Pubmed and Scielo database. Results: CD is a chronic inflammatory autoimmune disease that can generate extraintestinal manifestations as SFN. Small fiber neuropathy is a painful focal sensory neuropathy of slow progression, with distal predominance, symmetrical or not, beginning in adulthood and, sometimes, followed by autonomic dysfunction. Electroneuromyography studies (ENMG) suggest greater involvement of myelinated Adelta and C myelinated thin fibers, which is a precursor of sensory ganglionopathy in the dorsal root and can progress to large fiber neuropathy. The ENMG of SFN is usually normal because it is generally not demyelinating. To confirm the diagnosis, a skin biopsy that evaluates the fiber’s intra-epidermal density is indicated. Another exam is the quantitative test of the sudomotor reflex, capable of evaluating autonomic function. Finally, treatment should be directed to the underlying cause, optimization of the treatment of CD, and the management of symptoms, such as pain. Conclusions: The SFN, despite being an uncommon manifestation of CD, is possibly underdiagnosed due to the lack of studies evaluating this manifestation in celiac patients. Therefore, further studies are needed in order to instigate early diagnosis and adequate clinical management.

  • Estudo da prevalência de anemia gestacional e fatores associados na maternidade de referência do município de Joinville – SC

    by Heloisa Da Silva Schafaschek, Caroline Figueiredo da Silva, Gustavo Figueiredo da Silva, Maria Augusta Baptista Guimbala, Sthéfane De Almeida, Jean Carl Silva

    Objetivo: Avaliar a prevalência de anemia ferropriva em gestantes em uma maternidade de referência de Santa Catarina. Métodos: Realizou-se um estudo observacional, do tipo corte transversal, de março a maio de 2017, em uma maternidade pública do Sul do Brasil. Os dados foram obtidos através da revisão dos prontuários, carteirinhas de pré-natal, e aplicação de questionário padronizado às parturientes no período de pós-parto imediato. O desfecho analisado foi a presença de anemia gestacional e construído modelos de regressão logística multinominal para cálculo de razão de chance, e ajustada para variáveis de confusão. O nível de significância estatística adotado é de 5% (p<0,05). Resultados: Das 740 parturientes avaliadas, 263 (35,6%) tiveram valor de hemoglobina que indicasse anemia gestacional em um dos três trimestres. A população anêmica caracterizou-se por menor idade materna, escolaridade e porcentagem de puérperas casadas, maior prevalência de IMC abaixo do peso e início do pré-natal mais precoce. Conclusão: A prevalência de anemia gestacional nesse estudo foi de 36,5%.

  • Open Access

    SUPLEMENTAÇÃO DE SULFATO FERROSO NA GESTAÇÃO E ANEMIA GESTACIONAL: UMA REVISÃO DA LITERATURA

    by Heloisa Schafaschek, Caroline Figueiredo da Silva, Gustavo Figueiredo da Silva, Sthefane De Almeida, Maria Augusta Baptista Guimbala, Jean Carl Silva

    Este estudo objetivou realizar uma revisão da literatura sobre a influência da suplementação de ferro na prevenção da anemia ferropriva na gestação e seus efeitos associados na saúde do binômio mãe e feto. Para tanto, foram consultadas as bases de dados PUBMED, MEDLINE, SCIELO com os descritores “anemia”, “pregnancy” e “ferrous sulfate”, e selecionados os estudos que avaliavam os benefícios, malefícios e/ou a necessidade da suplementação ferrosa durante a gestação. Dos duzentos e um (201) artigos selecionados, onze (11) se enquadravam nos critérios. Dentre esses, quatro (04) abordaram apenas aspectos positivos, quatro (04) somente a perspectiva negativa e três (03) apresentaram ambos os lados. Ademais, oito (08) artigos fizeram ressalvas que contrapõem o atual modelo de uso rotineiro no Brasil, evidenciando que a suplementação individual de ferro seja preferida à rotineira. Isso porque, embora a anemia seja apontada como geradora de abortos espontâneos, restrição de crescimento intrauterino, parto pré-termo, pré-eclâmpsia, dentre outros, a suplementação também pode gerar efeitos negativos, os quais são resultantes tanto da hemoconcentração – em função do aumento expressivo dos níveis de hemoglobina – quanto dos efeitos colaterais da suplementação, como náuseas, vômitos, dor abdominal e constipação. Ainda, não houveram diferenças nos valores de hemoglobina e de prevalência de anemia significantes nos estudos avaliados, nem desfechos clinicamente relevantes em gestantes não anêmicas que receberam profilaxia com sulfato ferroso. Desse modo, o uso individualizado de acordo com cada paciente é mais plausível, pois a forma rotineira negligencia aspectos individuais, como a melhor frequência de uso, a demanda e os efeitos colaterais.